In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of AnaptysBio Inc (NASDAQ: ANAB) closed at $20.36 in the last session, up 1.04% from day before closing price of $20.15. In other words, the price has increased by $1.04 from its previous closing price. On the day, 0.6 million shares were traded. ANAB stock price reached its highest trading level at $20.545 during the session, while it also had its lowest trading level at $19.6001.
Ratios:
We take a closer look at ANAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.22 and its Current Ratio is at 8.22.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $25.
H.C. Wainwright Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $52 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when RENTON HOLLINGS sold 10,231 shares for $19.62 per share. The transaction valued at 200,714 led to the insider holds 4,965 shares of the business.
HOLLINGS C RENTON bought 10,231 shares of ANAB for $200,713 on Aug 08 ’25. On Jul 02 ’25, another insider, RENTON HOLLINGS, who serves as the Director of the company, sold 20,925 shares for $23.57 each. As a result, the insider received 493,191 and left with 4,965 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANAB now has a Market Capitalization of 569530304 and an Enterprise Value of 650765184. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.63. Its current Enterprise Value per Revenue stands at 5.284 whereas that against EBITDA is -7.606.
Stock Price History:
The Beta on a monthly basis for ANAB is -0.17, which has changed by -0.46066225 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, ANAB has reached a high of $40.70, while it has fallen to a 52-week low of $12.21. The 50-Day Moving Average of the stock is -14.06%, while the 200-Day Moving Average is calculated to be 2.23%.
Shares Statistics:
According to the various share statistics, ANAB traded on average about 583.47K shares per day over the past 3-months and 520740 shares per day over the past 10 days. A total of 27.97M shares are outstanding, with a floating share count of 25.59M. Insiders hold about 8.58% of the company’s shares, while institutions hold 119.89% stake in the company. Shares short for ANAB as of 1753920000 were 9562636 with a Short Ratio of 16.39, compared to 1751241600 on 9362857. Therefore, it implies a Short% of Shares Outstanding of 9562636 and a Short% of Float of 64.3.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of AnaptysBio Inc (ANAB) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.76, with high estimates of $1.18 and low estimates of -$1.91.
Analysts are recommending an EPS of between -$2.03 and -$6.23 for the fiscal current year, implying an average EPS of -$4.8. EPS for the following year is -$5.29, with 8.0 analysts recommending between -$2.7 and -$8.15.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for ANAB’s current fiscal year. The highest revenue estimate was $225.8M, while the lowest revenue estimate was $50.03M, resulting in an average revenue estimate of $111.15M. In the same quarter a year ago, actual revenue was $91.28M
